Literature DB >> 29962061

Medication-based versus target-based lipid management.

Sergio Fazio1, Michael D Shapiro1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29962061      PMCID： PMC7252911          DOI： 10.1111/1753-0407.12789

Source DB:  PubMed          Journal:  J Diabetes        ISSN： 1753-0407            Impact factor:   4.006


× No keyword cloud information.
  26 in total

1.  Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents.

Authors:  Paul M Ridker; Samia Mora; Lynda Rose
Journal:  Eur Heart J       Date:  2016-02-24       Impact factor: 29.983

2.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Authors:  Paul M Ridker; Brendan M Everett; Tom Thuren; Jean G MacFadyen; William H Chang; Christie Ballantyne; Francisco Fonseca; Jose Nicolau; Wolfgang Koenig; Stefan D Anker; John J P Kastelein; Jan H Cornel; Prem Pais; Daniel Pella; Jacques Genest; Renata Cifkova; Alberto Lorenzatti; Tamas Forster; Zhanna Kobalava; Luminita Vida-Simiti; Marcus Flather; Hiroaki Shimokawa; Hisao Ogawa; Mikael Dellborg; Paulo R F Rossi; Roland P T Troquay; Peter Libby; Robert J Glynn
Journal:  N Engl J Med       Date:  2017-08-27       Impact factor: 91.245

3.  Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.

Authors:  John W Eikelboom; Stuart J Connolly; Jackie Bosch; Gilles R Dagenais; Robert G Hart; Olga Shestakovska; Rafael Diaz; Marco Alings; Eva M Lonn; Sonia S Anand; Petr Widimsky; Masatsugu Hori; Alvaro Avezum; Leopoldo S Piegas; Kelley R H Branch; Jeffrey Probstfield; Deepak L Bhatt; Jun Zhu; Yan Liang; Aldo P Maggioni; Patricio Lopez-Jaramillo; Martin O'Donnell; Ajay K Kakkar; Keith A A Fox; Alexander N Parkhomenko; Georg Ertl; Stefan Störk; Matyas Keltai; Lars Ryden; Nana Pogosova; Antonio L Dans; Fernando Lanas; Patrick J Commerford; Christian Torp-Pedersen; Tomek J Guzik; Peter B Verhamme; Dragos Vinereanu; Jae-Hyung Kim; Andrew M Tonkin; Basil S Lewis; Camilo Felix; Khalid Yusoff; P Gabriel Steg; Kaj P Metsarinne; Nancy Cook Bruns; Frank Misselwitz; Edmond Chen; Darryl Leong; Salim Yusuf
Journal:  N Engl J Med       Date:  2017-08-27       Impact factor: 91.245

4.  Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.

Authors:  Stephen J Nicholls; Rishi Puri; Todd Anderson; Christie M Ballantyne; Leslie Cho; John J P Kastelein; Wolfgang Koenig; Ransi Somaratne; Helina Kassahun; Jingyuan Yang; Scott M Wasserman; Robert Scott; Imre Ungi; Jakub Podolec; Antonius Oude Ophuis; Jan H Cornel; Marilyn Borgman; Danielle M Brennan; Steven E Nissen
Journal:  JAMA       Date:  2016-12-13       Impact factor: 56.272

5.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Authors:  William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub
Journal:  N Engl J Med       Date:  2011-11-15       Impact factor: 91.245

6.  Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.

Authors:  Gregory G Schwartz; Laurence Bessac; Lisa G Berdan; Deepak L Bhatt; Vera Bittner; Rafael Diaz; Shaun G Goodman; Corinne Hanotin; Robert A Harrington; J Wouter Jukema; Kenneth W Mahaffey; Angèle Moryusef; Robert Pordy; Matthew T Roe; Tyrus Rorick; William J Sasiela; Cheerag Shirodaria; Michael Szarek; Jean-François Tamby; Pierluigi Tricoci; Harvey White; Andreas Zeiher; Philippe Gabriel Steg
Journal:  Am Heart J       Date:  2014-08-07       Impact factor: 4.749

7.  Cascade Screening for Familial Hypercholesterolemia and the Use of Genetic Testing.

Authors:  Joshua W Knowles; Daniel J Rader; Muin J Khoury
Journal:  JAMA       Date:  2017-07-25       Impact factor: 56.272

Review 8.  Cardiovascular and Metabolic Heterogeneity of Obesity: Clinical Challenges and Implications for Management.

Authors:  Ian J Neeland; Paul Poirier; Jean-Pierre Després
Journal:  Circulation       Date:  2018-03-27       Impact factor: 29.690

9.  Lipoprotein(a) as a cardiovascular risk factor: current status.

Authors:  Børge G Nordestgaard; M John Chapman; Kausik Ray; Jan Borén; Felicita Andreotti; Gerald F Watts; Henry Ginsberg; Pierre Amarenco; Alberico Catapano; Olivier S Descamps; Edward Fisher; Petri T Kovanen; Jan Albert Kuivenhoven; Philippe Lesnik; Luis Masana; Zeljko Reiner; Marja-Riitta Taskinen; Lale Tokgözoglu; Anne Tybjærg-Hansen
Journal:  Eur Heart J       Date:  2010-10-21       Impact factor: 29.983

10.  Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.

Authors:  Børge G Nordestgaard; M John Chapman; Steve E Humphries; Henry N Ginsberg; Luis Masana; Olivier S Descamps; Olov Wiklund; Robert A Hegele; Frederick J Raal; Joep C Defesche; Albert Wiegman; Raul D Santos; Gerald F Watts; Klaus G Parhofer; G Kees Hovingh; Petri T Kovanen; Catherine Boileau; Maurizio Averna; Jan Borén; Eric Bruckert; Alberico L Catapano; Jan Albert Kuivenhoven; Päivi Pajukanta; Kausik Ray; Anton F H Stalenhoef; Erik Stroes; Marja-Riitta Taskinen; Anne Tybjærg-Hansen
Journal:  Eur Heart J       Date:  2013-08-15       Impact factor: 29.983
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.